Mobilization and collection of peripheral blood progenitor cells for transplantation

The rapid growth of the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to mobilize and collect allogeneic peripheral blood stem cells (PBSCs) for transplantation has made it a new international standard. While the procedure remains safe, older donors, donors with significant comorbidities and pediatric donors are now often employed. This brings a new set of challenges in the donor evaluation, medical clearance, informed consent and collection process. Rare and unexpected severe adverse events related to rhG-CSF administration and PBSC apheresis have been described. Proper PBSC donor counseling, evaluation and care have become even more important.

show abstract

“…Most allogeneic donors are mobilized with 10 mcg/kg for 5 days [10][11][12][13][14]. Doses as high as 20 mcg/kg daily have been employed.…”

Section: Allogeneic Peripheral Blood Stem Cell Collectionmentioning

confidence: 99%

“…A combination of heparin and ACD-A or heparin alone may be used as an anticoagulant to reduce citrate toxicity. However, administration of heparin is also not without adverse effects like systemic anticoagulation and risk of bleeding [10].…”

Section: Anticoagulationmentioning

confidence: 99%

Allogeneic peripheral blood stem cell collection as of 2008

Rhodes

Anderlini

2008

Transfusion and Apheresis Science

View full text Add to dashboard Cite

show abstract

“…G-CSF has been used both pre-transplantation as a part of stem cell priming regimens and post transplantation to enhance stem cell engraftment to minimize the morbidity and mortality associated with prolonged neutropenia. [5][6][7][8][9] The use of G-CSF after HSCT accelerates granulocyte engraftment and recovery by 1-6 days in comparison with control. [10][11][12][13] However, most of the studies have been carried out on small numbers of patients and have varied significantly in patient demographics, G-CSF dosage regimen and other factors affecting outcomes.…”

Section: Introductionmentioning

confidence: 99%

Optimal use of G-CSF administration after hematopoietic SCT

Trivedi

Martinez

Corringham³

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…The rapid recovery of neutrophils and plts after AHSCT has been extensively studied and many reports have associated this with the total number of CD34 þ hemopoietic progenitor cells present in the infused autograft. [17][18][19]33 All our patients met the minimum recommended stem cell dose of 2.5 Â 10 6 CD34/kg, and this likely explains the early neutrophil and plt engraftment observed.…”

Section: Discussionmentioning

confidence: 59%

“…[14][15][16] Several authors have studied the pattern of granulocyte recovery following AHSCT, and this has led to the recognition that a minimum number of CD34 þ stem cells in the graft is required for re-establishment of hemopoiesis. [17][18][19] Although a rapid and consistent engraftment of all the cell lines has been reported to occur when a CD34 þ cell dose of above 5 million per kg body weight is infused, lower dose could result in comparable rate of granulocyte engraftment with a slower plt engraftment. 19 Early lymphocyte recovery following hemopoietic SCT has also been used as a predictive factor for prolonged survival in patients with many hematological malignancies.…”

Section: Introductionmentioning

confidence: 99%